

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

**(19) World Intellectual Property Organization**  
**International Bureau**



(43) International Publication Date  
15 July 2004 (15.07.2004)

PCT

(10) International Publication Number  
**WO 2004/058796 A1**

(51) International Patent Classification<sup>7</sup>: C07J 17/00

[KR/KR]; No. 2-902, Hanyang Apartment, Banpo 3-dong, Seocho-ku, 137-043 Seoul (KR). **KIM, Han-Kon** [KR/KR]; No. 201-903, Jukong Greenville, 1260, Metail-dong, Paldal-ku, Suwon-si, 442-370 Kyunggi-do (KR). **SIM, Young-Chul** [KR/KR]; No. 123-1402, Samik Apartment, Parktown, Sunae-dong, Bundang-ku, Sungnam-si, 463-020 Kyunggi-do (KR). **KANG, Hak-Hee** [KR/KR]; No. 111-2501, Daelim Apartment, Kumi-dong, Bundang-ku, Sungnam-si, 463-500 Kyunggi-do (KR). **LEE, Yong-Sung** [KR/KR]; No. 25-602, Hanyang Apartment, 151, Songpa-dong, Songpa-ku, 138-170 Seoul (KR).

**(21) International Application Number:** PCT/KR2003/001889

(74) Agents: YOON, Dong-Yol et al.; 9th Fl., Yosam Bldg., 648-23, Yoksam-dong, Kangnam-ku, Seoul 135-748 (KR).

**(22) International Filing Date:** 16 September 2003 (16.09.2003)

(81) **Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(23) Filing Language: Korean

**(30) Priority Data:**

26 December 2002 (26.12.2002) KR

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *with international search report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**(54) Title: PROMOTER FOR THE PRODUCTION OF HYALURONIC ACID CONTAINING GINSENOSIDES COMPOUND K**

**(57) Abstract:** There are provided a promoter containing ginsenoside compound K for the production of hyaluronic acid, and more particularly, a new efficacy of 20-O- $\beta$ -D-glucopyranosyl-20(S)-protopanaxadiol (compound K), a chief metabolite of ginseng saponin, to increase the expression of hyaluronic acid synthase gene in human cell and thereby to promote the production of hyaluronic acid, and an anti-aging agent containing the promoter for the production of hyaluronic acid as an effective ingredient.

## PROMOTER FOR THE PRODUCTION OF HYALURONIC ACID CONTAINING GINSENOSIDE COMPOUND K

### FIELD OF THE INVENTION

5

The present invention relates to a promoter containing ginsenoside compound K for the production of hyaluronic acid. More particularly, the present invention provides a new efficacy of 20-O- $\beta$ -D-glucopyranosyl-20(S)-protopanaxadiol (called "compound K"), a chief metabolite of ginseng saponin, 10 to increase the expression of the hyaluronic acid synthase (HAS) gene in human cells and thereby to promote the production of hyaluronic acid (HA), and provides a promoter containing compound K for the production of hyaluronic acid.

15

### BACKGROUND OF THE INVENTION

Hyaluronic acid is a nonsulfated glycosaminoglycan, linear polysaccharide with a very large molecular weight of 200,000 to 400,000 composed of repeating glucuronic acid and N-acetylglucosamine residues. 20 Hyaluronic acid is a major structural component of the extracellular matrix and involved in water retention, maintenance of the extracellular space and storage and diffusion of cell growth factors and nutrients, as well as in cell proliferation and differentiation, and migration.

In mammals, it has been reported that 50% or more of their hyaluronic 25 acid exists in the skin, particularly in epidermal extracellular space and dermal

connective tissue, and it is synthesized by keratinocyte and fibroblasts. Further, the concentration of hyaluronic acid in human skin decreases with aging, which causes the skin to lose its elasticity and to decrease water retention (*Biochem Biophys Acta* 279, 265-275, *Carbohydr Res* 159, 127-136, *Int J Dermatol* 33, 119-122).

The human joint capsule is composed of the outer fibrous layer and the inner synovial membrane, in which synovial fluid containing hyaluronic acid and glycoprotein, functions as a joint lubricant. It has however been reported that in osteoarthritis (degenerative arthritis), the production of hyaluronic acid 10 decreases and destruction by proteolytic enzymes is accelerated, so diminishing the concentration of hyaluronic acid in a joint. Therefore as the concentration of hyaluronic acid in a joint decreases, the joint cannot absorb or disperse shocks, so accelerating cartilage damage. Hence, hyaluronate injection was approved by the FDA in 1997 as a device for the relief of pain from 15 osteoarthritis and has been applied thereto. However, in the end, it may be more effective to increase the biosynthesis of hyaluronic acid.

The biosynthesis of hyaluronic acid in cultured epidermal cells has been reported to be increased by various growth factors and by trans-retinoic acid, N-methylserine and the like (*Biochem.J.* 258, 919-922, *Biochem.J.* 283, 20 165-170, *Biochem.J.* 307 817-821, *J. Biol. Chem.* 272, 4787-4794, *J Invest Dermatol* 92, 326-332, *Biol Pharm Bull* 17, 361-364, *Skin Pharmacol Appl Skin Physiol* 12, 276-283). Further, there were reports that estradiol and its derivatives applied on the skin might increase the biosynthesis of hyaluronic acid (*Steroids* 16, 1-3, *J Invest Dermatol* 87, 668-673, *Skin Pharmacol Appl Skin Physiol* 15, 175-183). However, the detailed mechanism for the

metabolism of hyaluronic acid has not yet been fully elucidated. It has been merely known that hyaluronic acid is synthesized at the inner surface of the plasma membrane by hyaluronic acid synthase and is extruded through the membrane into the extracellular space simultaneously with the ongoing 5 synthesis (*J. Biol. Chem.* 272, 13997-14000).

Currently, three different HAS genes have been identified in mammalian cells: HAS1, HAS2 and HAS3 which are highly homologous. In relation thereto, it was reported that HAS2 gene expression increased when an epidermal growth factor (EGF) was contained in a medium of epidermal cell 10 line culture (*J. Biol. Chem.* 276, 20428-20435). However, studies on distribution of hyaluronic acid in cells and tissues and on various factors and enzymes related to hyaluronic acid, for example HAS or factors regulating the activity of hyaluronic acid, remain insufficient up to now.

Therefore, several continuing studies have paid attentions to the 15 possibility of hyaluronic acid, and have extensively researched to find effective production and injection of hyaluronic acid and methods for increasing the biosynthesis of hyaluronic acid. However, obvious results are not yet known.

## SUMMARY OF THE INVENTION

20

Under these circumstances, the present inventors researched to find an effective method for supplying hyaluronic acid into the human body. As a result thereof, we found that compound K (20-O- $\beta$ -D-glucopyranosyl-20(S)-protopanaxadiol), a chief metabolite of ginsepeng saponin having 25 immunity-increasing, tumor angiogenesis-suppressing and cancerous cell

permeation-inhibiting effects, can increase the expression of gene coding hyaluronic acid synthase in human cells and thereby promote the production of hyaluronic acid in the human body. That is, the production of hyaluronic acid can be promoted by treatment with compound K, resulting in increasing the 5 concentration of hyaluronic acid in the human body. This result suggests that compound K can be applied to various purposes utilizing the efficacy of hyaluronic acid such as skin-care uses for improvement of skin elasticity and prevention of skin drying or skin aging and pharmaceutical uses for treatment or prevention of osteoarthritis. Based on this finding, the present invention has 10 been completed.

Therefore, an object of the present invention is to provide a new use of compound K to increase the expression of the hyaluronic acid synthase gene and thereby to promote the production of hyaluronic acid.

Another object of the present invention is to provide a promoter for the 15 production of hyaluronic acid containing compound K as an effective ingredient.

A further object of the present invention is to provide the possibility of compound K being applied to various purposes utilizing the efficacy of hyaluronic acid such as skin-care uses for improvement of skin elasticity and 20 prevention of skin drying or skin aging and pharmaceutical uses for treatment or prevention of osteoarthritis.

In order to accomplish the objects, the present invention provides a new efficacy of compound K, which already has been known to have efficacies such as an immunity-increasing effect, a tumor angiogenesis-suppressing effect 25 and a cancerous cell permeation-inhibiting effect. That is to say, the invention

provides a new efficacy of compound K to increase the expression of the hyaluronic acid synthase gene and thereby to promote the production of hyaluronic acid.


5

## DETAILED DESCRIPTION OF THE INVENTION

The following is a detailed description of the present invention.

Compound K, that is, 20-O- $\beta$ -D-glucopyranosyl-20(S)-protopanaxadiol represented by the following formula 1, is a chief metabolite of ginseng 10 saponin decomposed by human intestinal bacteria (Hasegawa, H., Sung, J. H., Matsumiya. S., Uchiyama. M.,(1996) *Planta Medica* 62, 453-457).

[Formula 1]



15

Ginsenosides and theirs derivatives derived from ginseng have the constitutions that sugar such as glucose, rhamnose, arabinose, xylose or the like is linked via ether bond to protopanaxadiol or protopanaxatriol, which are triterpenes of the dammarane series. So far, a total of a 29 types of 20 gensenosides have been isolated from ginseng (KOREA INSAM). Shibata, in

1964, named the components of ginseng saponin as "ginsenoside", which refers to glycoside contained in ginseng. Ginsenosides are classified into ginsenoside-Ro, which is a family of oleanane saponin, and ginsenoside-Ra, -Rb1, -Rb2, -Rc, -Rd, -Re, -Rf, -Rg1, -Rg2, -Rg3 and -Rh, according to the 5 order of movement in separating from TLC (thin-layer chromatography). Ginseng saponins have been known to exhibit different pharmacological efficacies depending on their type, number or the position of sugar bonded to aglycon. Many researches have been conducted on the pharmacological efficacy of major saponins plentifully contained in ginseng and easily isolated 10 therefrom. However, only a few researches have been conducted on the pharmacological efficacy of minor saponins contained only in red ginseng or of saponin metabolites decomposed by human intestinal bacteria.

Among ginseng saponins, compound K, i.e. 20-O- $\beta$ -D-glucopyranosyl-20(S)-protopanaxadiol, is composed of one sugar (glucose) bonded to 15 protopanaxadiol and has been known to exhibit pharmacological efficacy in suppressing cancerous cell proliferation, suppressing tumor cell proliferation and enforcing anticancer activity of anticancer agents. In particular, extensive studies on saponin metabolites revealed that the pharmacological efficacy of ginseng saponin is due to the metabolites decomposed by human intestinal 20 bacteria, not to the saponin itself (*Chem Pharm Bull* 38(10) 2859-2861, *Bio. Pharm. Bull* 25(6) 743-747).

The present inventors confirmed that HAS2 gene expression increased in compound K-treated human epidermal and dermal cell lines, i.e. keratinocyte cell line HaCaT and fibroblast cell line HDF. That is, treatment with compound 25 K for 24 hours induced 3-times and 2.5-times increases in HAS2 gene

expression in the cultured HaCaT and HDF cells respectively, in comparison with no treatment. Furthermore, HAS2 gene expression increased about 3-times and about 5-times during 24 hours and 48 hours incubations of HaCaT cells with treatment of 1 $\mu$ M compound K, respectively. These results show that 5 compound K has HAS2 gene expression-promoting efficacy in human cell. At the same time, it was confirmed that the concentration of hyaluronic acid in the human cell culture was increased by treatment of compound K.

In addition, the present inventors confirmed that the production of hyaluronic acid increased in the compound K-treated hairless mouse skin. 10 When compound K was introduced to a patch and applied onto the back skin of a hairless mouse, the production of hyaluronic acid increased about 3-times in the epidermis and dermis. These results indicate that compound K has HA production-promoting efficacy in a living body.

Finally, the present inventors confirmed that wrinkle, hydration, elasticity, 15 smoothness and brightness were improved when compound K-containing topical composition was applied onto the human skin.

Compound K employed in the present invention may be natural compound K or synthetic compound K obtained by the conventional method, but not limited thereto. Compound K may be obtained by dissolving purified 20 saponin of ginseng in aqueous solvent such as distilled water or buffer solution, or in a mixture of the aqueous solvent and organic solvent, and then reacting with at least one of naringinase separated from *Penicillium* and pectinase separated from *Aspergillus*, but not limited thereto.

The present invention shows that compound K can increase HAS2 gene 25 expression and promote the production of hyaluronic acid. Accordingly,

compound K can be incorporated, as an effective component, into skin-care topical compositions utilizing the efficacy of hyaluronic acid. For example, it can be added into skin-care topical compositions for improvement of skin elasticity and prevention of skin drying or skin aging. Further, it can be added 5 into medicaments for treatment or prevention of diseases, such as osteoarthritis, by administration of hyaluronic acid. However, it may not be limited thereto.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

10 Fig. 1 is a result of quantitative RT-PCR for HAS2 gene, in order to identify HAS2 mRNA expression in keratinocyte cell line HaCaT (Fig. 1a) and fibroblast cell line HDF (Fig. 1b) after treatment with various concentrations of compound K.

15 Fig. 2 is a result of quantitative RT-PCR for HAS1, HAS2 and HAS3 genes, in order to identify HAS mRNA expression in HaCaT cells after treatment with compound K for various time periods.

20 Fig. 3 shows the effect of compound K on the distribution of hyaluronic acid in the cultured HaCaT and HDF cells. After treatment with 1 $\mu$ M of compound K, the increased production of hyaluronic acid was confirmed by the immunocytochemical method and then the result was quantitated.

Fig. 4 shows the increased production of hyaluronic acid in the compound K-treated back skin of the hairless mouse, confirmed by immunohistochemical staining.

25 Fig. 5 shows morphological changes in human skin by treatment with the compound K-containing topical composition.

## PREFERRED EMBODIMENTS OF THE INVENTION

The present invention will be described in more detail by way of the  
5 following examples, which should not be considered to limit the scope of the  
present invention. Further, it will be apparent to one skilled in the art that  
various modifications and variations can be made within the scope of the  
present invention and without departing therefrom.

10 [Example 1] Preparation of compound K

10g of ginseng extract (red ginseng, white ginseng and the root hair and  
leaf of ginseng) was dissolved in 2ℓ of citrate buffer (pH 4.0). Thereto was  
added 10g of naringinase (Sigma, St. Louis, MO), 10g of pectinase (Novozyme,  
Copenhagen, Denmark) then the mixture was cultured in 38°C of water bath  
15 for 48 hours. After enzymatic hydrolysis was completed, the reaction mixture  
was extracted with 2ℓ of ethylacetate and then evaporated under a vacuum  
condition to give 2.8g of residue. For purification of compound K, the obtained  
product was subjected to silica gel column chromatography, eluted with  
chloroform- methanol (9:1) and then with chloroform-methanol (6:1), to give  
20 0.28g of pure compound K.

[Experimental Example 1] Effect of compound K on HAS2 gene expression in  
human epidermal cell line, HaCaT

Spontaneously immortalized human keratinocyte cell line, HaCaT, was provided by Dr. N.E. Fusenig (Deutsches Krebsforschungszentrum(DKFZ), Heidelberg, Germany) and human diploid fibroblast cell line, HDF, was provided by Dr. S.C. Park (Seoul National University, Seoul, Korea).

5 The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (HyClone), sodium bicarbonate (3.6g/ l ) and antibiotics of streptomycin (100 $\mu$ g/ml) and penicillin (100U/ml) (Life Technologies, Inc.) at 37°C in a humidified atmosphere containing 5% CO<sub>2</sub> and 95% air. The culture was changed with fresh medium  
10 every 3 days. On reaching the maximum cell-density, the cells were recultured at a 1:5 division ratio. 48 hours before treatment with compound K, the cells were seeded into a tissue culture flask at 1 $\times$ 10<sup>5</sup> cells per 75cm<sup>2</sup> and cultured in the medium with 10% fetal bovine serum for 24 hours. Subsequently, the cells were cultured in the serum-free medium for another 24 hours and then in fresh  
15 serum-free medium supplemented with 1 to 5 $\mu$ M of compound K for 3, 6, 12, 24 or 48 hours. As a control, the cells were cultured in the medium supplemented with 0.01% vehicle (dimethylsulfoxide, DMSO). In the control, no effect of DMSO on cell growth and differentiation was observed.

20 <Preparation of RNA>

HaCaT cells and HDF cells were washed twice with phosphate buffered saline (PBS) (Life Technologies, Inc.), and total cellular RNA was isolated with TRIzol<sup>®</sup> reagent (GibcoBRL Life Technologies, Grand Island, NY) according to manufacturer's instructions. RNA concentration was measured by  
25 spectrophotometry and RNA integrity was checked by agarose gel

electrophoresis.

5 <Effect of compound K on mRNA synthesis of HAS 1, HAS2 and HAS3, confirmed by quantitative reverse transcription – polymerase chain reaction (RT-PCR) method>

Quantitated total RNA was reverse transcribed, then RT-PCR was performed using HAS1-, HAS2- and HAS3-specific primers. In brief, 4 $\mu$ g of total RNA was reverse transcribed in 25 $\mu$ l of reaction mixture containing 2.5U/ $\mu$ l Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA), 1U/ $\mu$ l RNase inhibitor, 5mM MgCl<sub>2</sub>, 50mM KCl, 10mM Tris-HCl (pH8.3), 10 2.5 $\mu$ M oligo(dT) primers and 1mM dNTPs. The reaction mixture was gently incubated at 42°C for 60 min, to be subjected to reverse transcription. Then, the reverse transcriptase was inactivated by heating at 85°C for 5 min.

15 Subsequently, 5 $\mu$ l of the resulting mixture was subjected to PCR. Each PCR was performed using Perkin-Elmer Cycler 9600 (Perkin-Elmer Applied Biosystems, Foster, CA) in 50 $\mu$ l of reaction mixture containing 0.04U/ $\mu$ l AmpliTaq<sup>TM</sup> DNA polymerase (Perkin Elmer, Shelton, Connecticut), 50mM Tris (pH8.3), 0.25mg/ml BSA, 3mM MgCl<sub>2</sub>, 0.25mM dNTPs and 0.25 $\mu$ M sense or antisense PCR primers (Table 1) under a PCR thermal profile 20 consisting of denaturation at 95°C for 5 min prior to the initial cycle and 25~35 cycles of 45 sec at 95°C, 45 sec for 60°C and 1 min at 72°C. The PCR products were electrophoresed through agarose gels and visualized with ethidium bromide staining. The results are shown in Fig. 1 and Fig. 2. GAPDH is a criterion for standardization of the amplified products.

## [Table 1]

Sequences of HAS1-, HAS2- and HAS3-specific primers for quantitative RT-PCR

Primers		Sequences
HAS1	Forward	5'-ACCATCGCCTCGCCCTGCTCATCC-3'
	Reverse	5'-CCCGCTCCACATTGAAGGCTACCCA-3'
HAS2	Forward	5'-TTTCTTATGTGACTCATCTGTCACCGG-3'
	Reverse	5'-ATTGTTGGCTACCAGTTATCCAAAGGG-3'
HAS3	Forward	5'-CAGAAGGCTGGACATATAGAGGAGGG-3'
	Reverse	5'-ATTGTTGGCTACCAGTTATCCAAACG-3'

5

Fig. 1 is a result of quantitative RT-PCR for HAS2 gene, in order to identify HAS mRNA expression in keratinocyte cell line HaCaT (Fig. 1a) and fibroblast cell line HDF (Fig. 1b) after treatment with various concentrations of compound K, and shows the effect of the compound K on HAS2 mRNA level.

10 In this experiment, HAS2 mRNA was detected in a small amount in the control, but increased 3-times and 2.5-times in compound K-treated HaCaT cells and HDF cells, respectively.

Fig. 2 shows the effect of compound K on HAS1, HAS2 and HAS3 transcription in the HaCaT cells. HaCaT cells were cultured for 24 or 48 hours

15 in the medium with 0 or 1 $\mu$ M compound K added thereto, then total RNA was isolated therefrom. Total RNA was reverse transcribed and amplified for 30 PCR cycles. As a result, HAS2 transcription increased about 3-times and about

5-times during 24 hr and 48 hours incubation of HaCaT cells treated with compound K, respectively. However, compound K did not influence the HAS1 and HAS3 mRNA levels detected in small amount.

5 [Experimental Example 2] Effect of compound K on production of hyaluronic acid in human epidermal and dermal cell lines

HaCaT and HDF cells were washed with PBS then fixed in a fixative with 2% paraformaldehyde(v/v) and 0.5% glutaraldehyde(v/v) at room temperature for 20 min. After fixation, the cells were washed three times for 10 min each with 0.1 M sodium phosphate buffer (pH7.4), then blocked in 1% bovine serum albumin (w/v) containing 0.1% Triton X-100 (v/v) in the same buffer at room temperature for 30 min. Hyaluronan staining was carried out with a specific probe of biotinylated hyaluronan binding protein (bHABP) (Seikagaku, Tokyo, Japan). The bHABP probe, diluted to 5 $\mu$ g/ml in 3% 15 bovine serum albumin (w/v), was added to the fixed cells and was incubated overnight at 4°C. After washing, avidin-fluorescein isothiocyanate (FITC) was added. Images were analyzed with fluorescent microscope and are shown in Fig. 3.

Fig. 3 shows the effect of compound K on the distribution of hyaluronic 20 acid in the cultured HaCaT and HDF cells. HaCaT cells (Fig. 3a, Fig. 3b) and HDF cells (Fig. 3c, Fig. 3d) were cultured in the presence of 1 $\mu$ M compound K (Fig. 3b, Fig. 3d) or in the absence of compound K (Fig. 3a, Fig. 3c).

25 [Experimental Example 3] Effect of compound K on the production of hyaluronic acid in hairless mouse skin.

<Hairless mouse and its treatment>

Male albino Hos:hr-1 mice, 30 weeks old, were purchased from Biogenomics (Seoul, Korea) and had unrestricted access to standard rodent chow and water. After one week of acclimation under controlled conditions of 5  $24 \pm 2$  °C and 55 ± 10% humidity, 200  $\mu$ l of 1%(w/v) compound K solution in the vehicle (1,3-BG:ethanol=7:3) was topically applied onto the back of the mouse two times for 2 days. 24 hours after the final administration, each skin sample was collected.

10

<Immunohistochemical staining with hyaluronan binding protein on the compound K-treated skin>

Hyaluronan staining was carried out with bHABP(Seikagaku). Each skin sample was fixed with 2 % formaldehyde and 0.5 % glutaraldehyde in PBS, 15 embedded and sectioned. After deparaffinization, sections were incubated in 0.3% H<sub>2</sub>O<sub>2</sub> in methanol at room temperature for 30 min, washed with PBS, then blocked in 1% bovine serum albumin. Subsequently the sections were incubated in 5mg/ml bHABP in PBS at 4 °C then, after washing, incubated with streptoavidin-peroxidase, diluted to 1/300 in PBS at room temperature, for 20 30 min. After washing, each slide was reacted with 3,3'-diaminobenzidine tetrahydrochloride(DAB) at room temperature for 5 min. After washing with distilled water, staining was carried out with Mayer's hematoxylin.

<Analysis of image and data obtained by immunohistochemical staining>

25 Stained slides were quantitatively characterized via digital image analysis

using ImagePro-Plus (Media Cybernetics, Silver Spring, MD). Images were captured through an Olympus BH-2 microscope fitted with a MicroImage video camera (Boyertown, PA). Parameters, such as total area, total stained area, and intensity of stain, were taken from a series of 10 random images on 5 several slides to obtain a mean value for statistical comparison. Staining score is determined by the following formula 1:

[Equation 1]

Intensity of stain X (total stained area / total area)

10

One-way ANOVA with post-hoc Duncan test was performed using SigmaStat (SPSS Inc., Chicago, IL). Data were expressed as the mean $\pm$ SEM. Significance was considered at  $p<0.05$ .

Fig. 4 shows hyaluronic acid widely deposited in the epidermis and dermis. It 15 shows that hyaluronic acid significantly increased in compound K-treated hairless mouse skin. As shown in Fig. 4a and Fig. 4b, the amount of hyaluronic acid increased predominantly in the extracellular papillary dermis and in the viable epidermis of the compound K-treated murine skin. Fig. 4c is a result of quantitative image analysis, showing that the amount of HA increased 3-folds in epidermis and dermis of the 20 compound K-treated murine skin, respectively, as compared with the untreated skin. ( $p<0.05$ ).

The above results confirm that treatment of the skin cells with compound K increases the expression of hyaluronic acid synthase, HAS2 gene, resulting in promotion of the production of hyaluronic acid in the epidermis and dermis of the 25 skin.

[Experimental Example 4] Evaluation for skin-care efficacy

<Topical Application >

5        In order to evaluate the efficacy of the cosmetic composition containing compound K, a clinical trial was conducted with forty-nine (49) healthy Korean females aged from 31 to 37 years and having facial wrinkle and fine wrinkle. They were divided into three groups by skin type: normal skin, dry skin and combination skin and used two kinds of oily-water emulsions containing 0.03% compound K or  
10      none. Before the trial, all the volunteers were evaluated for facial wrinkle and fine wrinkle with a global photodamage score. All the scores were obtained before use and 4, 8 and 12 weeks after use. Each volunteer applied test samples onto the facial skin twice per day (morning and evening) at their homes, and particularly onto the wrinkles of the eye rims.

15

<Efficacy evaluation>

20       Skin-care efficacies such as facial wrinkle, fine wrinkle, hydration, elasticity, smoothness, roughness and brightness were evaluated by the volunteers and skin expert inspectors. Difference before and after using topical samples and improvement were determined by photometry evaluation with Camscope®(model DCS-105) and by image analysis of silicon replica with Skin-Visiometer SV 600(Courage & Khazaka, Germany).

25      Fig. 5 shows a result of evaluation with global photodamage score conducted by skin expert inspectors. In a comparison of initial values measured before use and values measured after 12 weeks of use of the emulsions with or

without compound K as a control, it was found that compound K induced statistically significant decrease in facial wrinkle and fine wrinkle (Fig. 5a). In the clinical trial, 76% of volunteers after 8 weeks of use and 92% of volunteers after 12 weeks of use gave positive and affirmative estimate (Fig. 5b)

5 In skin replica analysis, it was found that total wrinkle decreased statistically significantly after 8 weeks of use. 92% of volunteers answered improvement in skin smoothness; 68% answered improvement in skin brightness; 68% answered improvement in skin elasticity; and 94% answered improvement in skin roughness. 88% of volunteers answered increase in skin  
10 moisturizing capacity.


#### **INDUSTRIAL APPLICATION OF THE INVENTION**

As above described, compound K, a chief metabolite of ginseng saponin,  
15 can increase expression of gene coding hyaluronic acid synthase 2 and thereby activate the production of hyaluronic acid in a living body. Therefore, compound K can be used for effective prevention of skin elasticity reduction, water retention reduction and skin aging. Further, it can be effectively used for prevention and treatment of osteoarthritis, utilizing hyaluronic acid for  
20 remedial value.

## CLAIMS

1. A promoter for the production of hyaluronic acid containing compound K (20-O- $\beta$ -D-glucopyranosyl-20(S)-protopanaxadiol) represented by the  
5 following formula 1 as an effective ingredient :

[Formula 1]



2. The promoter according to Claim 1, wherein said compound K promotes the  
10 production of hyaluronic acid by increasing the expression of hyaluronic acid  
synthase gene.

3. An anti-osteoarthritis agent containing the promoter for the production of  
hyaluronic acid according to Claim 1.


15

4. An anti-aging agent containing the promoter for the production of  
hyaluronic acid according to Claim 1.


## FIGURES

**FIG. 1**

**a**



**b**







**FIG. 2****HAS1****HAS2****HAS3****GAPDH****SM    0H    24H    48H**

FIG. 3


a



b



c



d



e




FIG. 4





FIG. 5



## Sequence Listing

<110> AMOREPACIFIC CORPORATION

<120> Promoter for the production of hyaluronic acid containing  
ginsenoside Compound K

<160> 6

<170> KopatentIn 1.71

<210> 1

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR amplification primer for amplifying the gene of has 1

<400> 1

accatgcct tcgcccgtct catcc

25

<210> 2

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR amplification primer for amplifying the gene of has 1

<400> 2

cccggtttccat attgaaggct accca

25

<210> 3

<211> 30

<212> DNA

<213> Artificial Sequence

## Sequence Listing

&lt;220&gt;

&lt;223&gt; PCR amplification primer for amplifying the gene of has 2

&lt;400&gt; 3

tttccttatg tgactcatct gtctcaccgg

30

&lt;210&gt; 4

&lt;211&gt; 28

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; PCR amplification primer for amplifying the gene of has 2

&lt;400&gt; 4

attgttgct accagttat ccaaaggg

28

&lt;210&gt; 5

&lt;211&gt; 26

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; PCR amplification primer for amplifying the gene of has 3

&lt;400&gt; 5

cagaaggctg gacatataga ggaggg

26

&lt;210&gt; 6

&lt;211&gt; 27

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

## Sequence Listing

<223> PCR amplification primer for amplifying the gene of has 3

<400> 6

atgttggct accagttat ccaaacg

27

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/KR03/01889

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7 C07J 17/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC C07J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
Korean patents and applications for inventions since 1975

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
CAS- on- Line, Medline

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	KR 2003-65273 A (Il Hwa Co., Ltd.) 06 Aug. 2003 See claim 3 and Example 7	4
P, X	KR 2003-80429 (Pacific Corporation) 17. Oct. 2003 See examples and claim 11	4
A	Biochemical Pharmacology (2000) Vol.60(5):677-685. CODEN: BCPA6. ISSN:0006-2952 S. J. Lee et al "Induction of apoptosis by a novel intestinal metabolite of ginseng saponin via cytochrome c-mediated activation of caspase-3 protease"	1- 4
A	Wakan Iyakugaku Zasshi (2000) Vol.18(6), 218-278 CODEN: WIZAEL, ISSN:1340-6302 Kasegawa Hideo : "Metabolic activation of ginsenoside against cancer:intestinal bacterial deglycosylation and hepatic fatty-acid esterification"	1- 4
A	WO 97/31013 A1 (Il Hwa Co., Ltd.) 28. Aug 1997	1 - 4

Further documents are listed in the continuation of Box C.

See patent family annex.

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search 23 DECEMBER 2003 (23.12.2003)	Date of mailing of the international search report 23 DECEMBER 2003 (23.12.2003)
Name and mailing address of the ISA/KR  Korean Intellectual Property Office 920 Dunsan-dong, Seo-gu, Daejeon 302-701, Republic of Korea Facsimile No. 82-42-472-7140	Authorized officer CHO, Myung Sun Telephone No. 82-42-481-5594



**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.

PCT/KR03/01889

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
KR 2003-65273 A	06.08.2003	JP2003-238424 A	27.08.2003
W09731013A1	28.08.1997	CA 2218724 A1 CN 1182433 A	28.08.1997 20.05.1998

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**